CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 607 enrolled
Drug / intervention
Screening for trilateral retinoblastoma with MRIother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06367569
NCT06367569N/ACompleted

Multicenter Evaluation of Baseline MRI Screening With Extended Follow-up of Pineal Cysts for Early Detection of Pineoblastoma in Children With Retinoblastoma

Amsterdam UMC, location VUmc·observational·Posted Apr 16, 2024·Updated Apr 16, 2024

In Brief

An observational study evaluating Screening for trilateral retinoblastoma with MRI for Retinoblastoma. Completed, enrolled 607 participants across 1 site.

Detailed Summary

Rationale: Currently baseline brain MRI (magnetic resonance imaging) with extended follow-up of pineal cysts is systematically performed in all new retinoblastoma (Rb) patients, because children with hereditary retinoblastoma have an increased risk of primitive neuroectodermal tumors (PNET) that are histopathologically identical to the retinal tumors (1). The prevalence of developing a PNET in combination with unilateral or bilateral hereditary Rb is 5-15% (2). Treatment is difficult and the prognosis is poor as only few survivors are reported. Only patients with small asymptomatic PNETs (\<15 mm) are potentially curable. Objective: The main objective of this prospective multicenter study is to evaluate the current strategy of baseline MRI screening of the brain in newly diagnosed retinoblastoma patients, with extended follow-up of selected patients with simple and complicated pineal cysts. Study design: The investigators propose a prospective cohort study (part of a larger multicenter study) to investigate the diagnostic accuracy and survival of baseline MRI screening of the pineal gland in new patients with retinoblastoma, with extended follow-up of selected patients with pineal cysts for early detection of pineoblastoma. Study population: Within the European Retinoblastoma Imaging Collaboration (ERIC) about 150 new retinoblastoma patients are diagnosed every year. About 10 percent of all new retinoblastoma patients will be diagnosed at the VUmc. According to our sample size calculations the investigators will need 334 Rb patients. Main study parameters/endpoints: The primary endpoint of the study is pineoblastoma or supra- / parasellar PNET on MRI (index test). Because a gold standard will not be available, tumor cells in cerebrospinal fluid, histopathological confirmation, clinical disease progression during follow-up, and/or follow-up MRI diagnostics will be used as a composite reference standard in case of a positive index test and clinical diagnosis of pineoblastoma or supra- / parasellar PNET within one year of the last MRI will be used as a composite reference standard in case of a negative index test.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRetinoblastoma
CountriesNetherlands
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 16, 2024
Enrollment StartOct 1, 2012
Primary CompletionSep 1, 2023
TodayJul 2, 2026
Enrollment to primary: 10.9 yearsPosted 2.2 years ago

Interventions

Screening for trilateral retinoblastoma with MRIother

The diagnostic accuracy of the screening program, baseline screening with MRI followed by follow-up of suspicious pineal glands in heritable retinoblastoma patients.